Skip to main content

Diabetes

  • Hypoglycemic events can disrupt work productivity for diabetics, survey finds

    COPENHAGEN, Denmark — A new survey sponsored by drug maker Novo Nordisk, which polled Type 1 and Type 2 diabetes patients in the United States, United Kingdom, Germany and France, found that about 1-in-5 respondents regularly are unable to attend a full day of work due to disruption caused by episodes of dangerously low blood sugar, also known as hypoglycemic events.

  • Study: Amylin's metreleptin improves diabetes, lipid control among patients

    SAN DIEGO — An investigational drug improved diabetes and lipid control in patients with partial lipodystrophy, according to a new study.

    Amylin Pharmaceuticals announced Saturday results of a study of metreleptin, an analog of the human hormone leptin. Results of the study were presented at the 93rd annual meeting and expo of the Endocrine Society in Boston.

  • Diamyd Medical earns back rights to diabetes drug from J&J subsidiary

    STOCKHOLM — Swedish drug maker Diamyd Medical has regained control of its investigational drug for Type 1 diabetes following Johnson & Johnson’s termination of a development deal between the two companies.

  • MinuteClinic offers free diabetes monitoring package

    WOONSOCKET, R.I. — CVS Caremark's MinuteClinic locations are offering a free diabetes monitoring package this summer, the company announced on Friday.

    The monitoring package administered by a MinuteClinic practitioner includes hemoglobin A1C and blood glucose tests, a blood pressure check, body mass index, cholesterol test, comprehensive foot exam and microalbumin test (kidney function check). The practitioner also will conduct a review of lifestyle factors and give immediate results and recommendations.

  • HbA1C test may not be useful among dialysis patients with diabetes

    WINSTON-SALEM, N.C. — The gold standard long-term glucose monitoring test for patients with diabetes proved to be of limited value in dialysis patients, according to a new study at Wake Forest Baptist Medical Center released Wednesday.

  • Insulet acquires Neighborhood Diabetes

    BEDFORD, Mass. — A company that develops insulin-pump technology without tubing, such as the OmniPod insulin management system, has acquired a durable medical equipment distributor that specializes in direct-to-consumer sales of diabetes supplies.

  • Aristides Spanellis prohibited from buying, selling LifeScan's blood-glucose monitoring test strips

    MILPITAS, Calif. — LifeScan announced a major settlement regarding counterfeit packaged LifeScan blood-glucose monitoring test strips sold by Aristides Spanellis.

  • Sanofi: Lyxumia won't significantly increase hypoglycemia risk

    PARIS — New results from a late-stage clinical trial of a Sanofi drug for Type 2 diabetes indicated that the drug can reduce blood sugar in patients without increasing the risk of causing the blood sugar levels to dip too low, the French drug maker said Tuesday.

X
This ad will auto-close in 10 seconds